deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT05306353

CD40L Antagonism in Rheumatoid Arthritis (RA) (CONTROL-RA)

Combining a CD40L-Binding Protein (VIB4920) With a TNF-alpha Inhibitor for the Treatment of Inadequately Controlled Rheumatoid Arthritis (ITN092AI)

Sponsor: Immune Tolerance Network (ITN)

Updated 23 times since 2022 Last updated: Jan 27, 2026 Started: Jul 25, 2023 Primary completion: Jul 28, 2025 Completion: Jul 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study is being closed early due to insufficient participant enrollment across study sites.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is terminated or withdrawn. The trial is conducted by Immune Tolerance Network (ITN) and has accumulated 23 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

23 versions recorded
  1. Feb 2026 — Present [monthly]

    Terminated PHASE2

    Status: WithdrawnTerminated

  2. Sep 2025 — Feb 2026 [monthly]

    Withdrawn PHASE2

    Status: RecruitingWithdrawn

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. May 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  5. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE2

    Status: Active Not RecruitingRecruiting

Show 18 earlier versions
  1. Oct 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Not Yet RecruitingActive Not Recruiting

  5. Dec 2023 — Mar 2024 [monthly]

    Not Yet Recruiting PHASE2

  6. Nov 2023 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE2

    Status: RecruitingNot Yet Recruiting

  7. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  8. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  10. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  11. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  12. Mar 2023 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE2

  13. Feb 2023 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE2

  14. Dec 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

  15. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE2

  16. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE2

  17. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  18. May 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immune Tolerance Network (ITN)
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .